These results indicate that ELAVL2 protein expression level is associated with tumor progression and also favorable survival rate of glioma patients, and thus, may be used as a prognostic and diagnostic biomarker for gliomas. This evidence concerns the gene ELAVL2 and central nervous system cancer.